John S. Macdonald

TL;DR: The number of lymph nodes analyzed for staging colon cancers is, itself, a prognostic variable on outcome and may be an important variable to include in evaluating future trials.

TL;DR: 5-FU CI is superior to 5-FU bolus in terms of tumor response and achieves a slight increase of overall survival, and the hematologic toxicity is much less important in patients who receive 5-fu CI, but hand-foot syndrome is frequent in this group of patients.

TL;DR: This is a mature study with all patients able to be followed for more than 5 years, and the evidence for therapeutic benefit was strong, but it was possible that the authors were only prolonging the interval to cancer recurrence and death rather than actually improving cure rates.

TL;DR: Overall survival and relapse-free survival data demonstrate continued strong benefit from postoperative radiochemotherapy and subset analyses show robust treatment benefit in most subsets, with the exception of patients with diffuse histology who exhibited minimal nonsignificant treatment effect.

TL;DR: Results indicate that intensive-course 5FU plus low-dose leucovorin is effective in preventing tumor relapse and improving survival in patients with high-risk colon cancer.